PMID- 7907650
OWN - NLM
STAT- MEDLINE
DCOM- 19940420
LR  - 20190630
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 62
IP  - 4
DP  - 1994 Apr
TI  - Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in 
      extracellular concentrations of dopamine produced by the amphetamine analogue 
      3,4-methylenedioxymethamphetamine.
PG  - 1382-9
AB  - 5-Hydroxytryptamine2 (5-HT2) receptor antagonists have been shown to interfere 
      with the stimulation of striatal dopamine synthesis and release produced by the 
      amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA). To localize the 
      receptors responsible for the attenuation of MDMA-induced release, 5-HT2 receptor 
      antagonists were infused via the microdialysis probe directly into the brains of 
      awake, freely moving rats before the systemic administration of MDMA. 
      Intrastriatal infusions of the selective 5-HT2 antagonist MDL 100,907 produced a 
      concentration-dependent inhibition of MDMA-induced dopamine release. Similar 
      results were observed with intrastriatal infusions of the 5-HT2 antagonist 
      amperozide. In contrast, infusion of MDL 100,907 into the mid-brain region near 
      the dopaminergic cell bodies was without effect on the MDMA-induced elevation of 
      extracellular dopamine in the ipsilateral striatum. Neither antagonist attenuated 
      basal transmitter efflux nor the MDMA-stimulated release of [3H]dopamine from 
      striatal slices in vitro indicating that the in vivo effect of the antagonists 
      was not due to inhibition of the dopamine uptake carrier. Intrastriatal infusion 
      of tetrodotoxin reduced both basal and MDMA-stimulated dopamine efflux and 
      eliminated the effect of intrastriatal MDL 100,907. The results indicate that 
      5-HT2 receptors located in the striatum augment the release of dopamine produced 
      by high doses of MDMA. Furthermore, these 5-HT2 receptors appear to be located on 
      nondopaminergic elements of the striatum.
FAU - Schmidt, C J
AU  - Schmidt CJ
AD  - CNS Research, Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215.
FAU - Sullivan, C K
AU  - Sullivan CK
FAU - Fadayel, G M
AU  - Fadayel GM
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Fluorobenzenes)
RN  - 0 (Piperidines)
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Serotonin Antagonists)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 4368-28-9 (Tetrodotoxin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - EW71EE171J (volinanserin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - 3,4-Methylenedioxyamphetamine/analogs & derivatives/pharmacology
MH  - Animals
MH  - Corpus Striatum/drug effects/*metabolism
MH  - Dialysis
MH  - Dopamine/*metabolism
MH  - Extracellular Space/*metabolism
MH  - Fluorobenzenes/pharmacology
MH  - Homovanillic Acid/pharmacology
MH  - Kinetics
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Piperidines/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Serotonin/physiology
MH  - *Serotonin Antagonists
MH  - Tetrodotoxin/pharmacology
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - 10.1046/j.1471-4159.1994.62041382.x [doi]
PST - ppublish
SO  - J Neurochem. 1994 Apr;62(4):1382-9. doi: 10.1046/j.1471-4159.1994.62041382.x.